Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

糖尿病肾病：药物发现和临床开发挑战

基本信息

批准号：
8785323
负责人：
Frank C Brosius
金额：
$ 1万
依托单位：
NEW YORK ACADEMY OF SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-01 至 2015-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8785323
关键词：
Academia Academy Albuminuria Angiotensins Animal Model Anti-Inflammatory Agents Anti-inflammatory Area Award Basic Science Benefits and Risks Biological Markers Blood capillaries Caring Cells Child Chronic Kidney Failure Clinic Clinical Clinical Data Clinical Investigator Clinical Trials Collaborations Communities Complications of Diabetes Mellitus Congresses Consensus Coupled Data Development Diabetes Mellitus Diabetic Nephropathy Diagnostic Digestive System Disorders Disabled Persons Disease Disease Association Drug Industry Educational workshop End stage renal failure Epidemic Event Faculty Family Fellowship Female Fibrosis Fostering Future Goals Government Healthcare Systems Incidence Industry Inflammation Institutes International Kidney Kidney Diseases Knowledge Life Medical Research Mentors Metabolism Minority Groups Mission Molecular Monitor Multimedia New York New York City Obesity Participant Pathway interactions Patients Pharmacologic Substance Physiology Pre-Clinical Model Prevalence Process Prognostic Marker Progressive Disease Public Health Publications Publishing Research Research Personnel Research Training Resolution Risk Role Science Scientist Signal Pathway Signal Transduction Technical Expertise Technology Therapeutic Tissues Translational Research Translations Travel Tubular formation Underrepresented Minority United States Woman abstracting advanced disease base capillary career cell type data exchange discount drug candidate drug development drug discovery improved innovation insight knowledge translation lectures mTOR inhibition meetings new technology new therapeutic target novel novel therapeutics outcome forecast posters prevent public health relevance repository standard of care symposium targeted delivery treatment strategy

项目摘要

DESCRIPTION (provided by applicant): Diabetic nephropathy (DN), a well-known complication of diabetes, is the leading cause of chronic renal failure and end-stage renal disease (ESRD). The limited efficacy of the standard of care, which only delays the progression to ESRD to a limited extent, coupled with our incomplete understanding of this multifaceted disease, highlights the importance of unraveling novel therapeutic targets. This 1-day scientific symposium titled, "Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges" will be presented by the New York Academy of Sciences on December 9, 2014, in New York City. This symposium will blend new technologies, target-disease associations, physiology-based insights, and identify novel targets, with the goals of identifying and delivering novel drug candidates into the clinic, improving current treatments, and developing new therapeutic strategies. The event will convene approximately 150 attendees ranging from basic scientists and clinical investigators in academia, industry, and government; to pharmaceutical strategists, and regulatory experts. The three central aims of this conference are to: (i) provide neutral forum through lectures, interactive debates, and networking activities for discussing current hurdles and emerging innovative approaches to DN-targeted therapy, such as preclinical models and clinical trials, signaling pathways, identification of druggable targets, capillary loss and excess anti-angiogenic activity associated with advanced disease states, and targeting the renal microvasculature; (ii) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations, travel fellowships, career mentoring activities, and discounted registration; and (iii) foster collaboratin among international investigators from all sectors to promote the translation of research into safer and more efficient diabetic kidney disease therapeutics. The symposium goals align well with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to support medical research and research training. The NIDDK's goal to disseminate science-based information on diabetes and kidney diseases will be met through the symposium's simulcast and archival as a webinar and open-access, online, multimedia Academy eBriefing, and publication of an open-access, Section 508- compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the symposium to the global research and medical communities. This symposium is especially timely given that a wealth of new data has emerged within distinct research areas (e.g., novel cell types, targets, and therapies) and from varied scientific approaches (e.g., animal models, novel target tissues). A collaborative examination of this new information among all diabetic kidney disease stakeholders is therefore of significant value for guiding research forward in the field - particularly with respect to potential novel targets and delivery of novel drug candidates into the clinic.

描述（由申请人提供）：糖尿病性肾病（DN）是一种众所周知的糖尿病并发症，是慢性肾衰竭和终末期肾脏疾病（ESRD）的主要原因。护理标准的有限疗效仅在有限的程度上延迟了ESRD的进展，再加上我们对这种多方面疾病的不完全理解，突显了揭示新型治疗靶标的重要性。纽约科学院将于2014年12月9日在纽约市提出，这场为期1天的科学研讨会为“糖尿病肾脏疾病：药物发现和临床发展挑战”。该研讨会将融合新技术，目标疾病协会，基于生理的见解，并确定新目标，并识别和交付的目标新的候选药物进入诊所，改善当前治疗方法并制定新的治疗策略。该活动将召集大约150名参加者，包括学术界，工业和政府的基础科学家和临床研究人员；致药策略师和监管专家。这次会议的三个中心目标是：（i）通过讲座，互动辩论和网络活动提供中性论坛，以讨论当前的障碍和新兴的DN靶向治疗的创新方法，例如旋链型模型和临床试验，信号途径，识别药物损失，毛细管损失，毛细管损失，墨西哥流失，毛细管损失，墨西哥capi骨损失，毛细管损失，以及与晚期疾病状态相关的过量抗血管生成活性，并针对肾脏微脉管系统；（ii）通过简短的演讲，海报演讲，旅行奖学金，职业指导活动和折扣注册来展示和鼓励早期职业，女性和代表性不足的少数群体调查员的参与；（iii）在所有部门的国际研究人员中培养合作，以促进研究将研究转化为更安全，更有效的糖尿病肾脏疾病疗法。研讨会的目标与美国国家糖尿病与消化研究所和肾脏疾病（NIDDK）的使命非常吻合，以支持医学研究和研究培训。 The NIDDK's goal to disseminate science-based information on diabetes and kidney diseases will be met through the symposium's simulcast and archival as a webinar and open-access, online, multimedia Academy eBriefing, and publication of an open-access, Section 508- compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the symposium全球研究和医疗社区。尤其是及时的，鉴于在不同的研究领域（例如新型细胞类型，靶和疗法）以及不同的科学方法（例如动物模型，新型靶组织）中出现了大量新数据。因此，在所有糖尿病肾脏病利益相关者中对这一新信息的协作检查对于指导该领域的研究具有重要价值，尤其是在潜在的新型目标和新型药物候选者进入诊所中。